Trusted Press Release Distribution   Plans | Login    

Briefing Search
Keyword:
Category:

       

    
Author Details
Pareesh Phulkar
pareesh@coherentmarketinsights.com
www.coherentmarketinsights.com/

Bookmark and Share
Inactivated Vaccine Market Industry Growth, Size, Share, Outlook, and Analysis | 2018-2026
Introduction of new inactivated vaccines after completion of clinical studies are expected to boost growth of the inactivated vaccines market over the forecast period.


Introduction of new inact
BriefingWire.com, 9/13/2019 - Introduction of new inactivated vaccines after completion of clinical studies are expected to boost growth of the inactivated vaccines market over the forecast period. For instance, in 2017, Merck’s investigational inactivated varicella zoster virus vaccine (V212) showed a decrease in the incidence of herpes zoster case by an estimated 64% in immunocompromised subjects in the first phase 3 trial. Clinical studies also revealed that V212 lessens the incidence of herpes zoster pain by around 69.5%. Moreover, V212 demonstrated 83.7% reduction in the incidence of post herpetic neuralgia.

Get PDF Brochure of This Business Report: https://www.coherentmarketinsights.com/insight/request-pdf/1905

Rising prevalence of various viral and bacterial diseases around the globe have increased the demand for inactivated vaccines, which in turn will fuel the market growth. For instance, according to the World Health Organization (WHO) report in 2018, annual epidemics due to influenza were estimated to result in around 3 to 5 million cases of severe illness and around 290,000 to 650,000 deaths. Moreover, WHO 2018 report also showed that around 21 million cases and 222,000 typhoid-related deaths occur annually worldwide.

Get PDF Brochure of This Business Report: https://www.coherentmarketinsights.com/insight/request-pdf/1912

Department of Health and Human Services shifted fund of around US$ 81 million from other projects, to continue the work on developing vaccines to fight Zika virus. Asia Pacific is expected to witness growth in the market, followed by Europe, owing to growing activities in the healthcare research and development of new innovative products. For instance, in 2013, Bharat Biotech launched JENVAC vaccine to provide long-term protection and immunogenicity against Japanese encephalitis. The important benefit of this novel fully indigenous inactivated vaccine is that it can be administered during disease epidemics, as it is an inactivated vaccine and is highly purified.

Inactivated Vaccine Market – Taxonomy: On the basis of vaccine type, the global inactivated vaccine market is segmented into: Viral Vaccine, Bacterial Vaccine,. On the basis of method of inactivation, the global inactivated vaccine market is segmented into: Solvent Detergent Method, Radiation Method, pH Concentration, Heat Inactivation, Others,.

Major players operating in the global inactivated vaccine market include GlaxoSmithKline Plc, Seqirus, Valneva SE, Pfizer Inc., Merck & Co., Inc., Emergent BioSolutions, Bharat Biotech, and Sanofi. Major market players are involved in adopting market strategies such as mergers, acquisitions, partnership, collaborations, and development of new products with leading companies and research institutes, in order to retain dominant position in the market. For instance, in 2017, the U.S. Food and Drug Administration (FDA) approved GlaxoSmithKline Plc’s Shingrix, a zoster vacc

Browse more detail information about: https://www.coherentmarketinsights.com/ongoing-insight/inactivated-vaccine-market-1905

 
 
FAQs | Contact Us | Terms & Conditions | Privacy Policy
© 2019 Proserve Technology, Inc.